What is dMed Biopharmaceutical?
dMed Biopharmaceutical operates as a sophisticated global clinical research service provider, functioning as a strategic partner for biopharmaceutical firms aiming to accelerate their innovation pipelines. The company specializes in delivering professional clinical trial expertise, utilizing a patient-centered approach that integrates high-quality data delivery with risk mitigation strategies. With a presence spanning over 40 countries, dMed provides the infrastructure necessary for complex, multi-regional trials, ensuring that clients can achieve regulatory milestones and clinical breakthroughs with greater efficiency. Their market position is defined by a unique blend of deep scientific expertise and operational agility, allowing them to address the evolving needs of the global healthcare industry.
How much funding has dMed Biopharmaceutical raised?
dMed Biopharmaceutical has raised a total of $158M across 3 funding rounds:
Series A
$8M
Series B
$50M
Series C
$100M
Series A (2016): $8M with participation from Tairui Investment, Qiming Venture Capital, and Zai Lab
Series B (2019): $50M led by Legend Capital, Qiming Venture Partners, Vivo Capital, and Lilly Asia Ventures
Series C (2020): $100M supported by Kaiser Foundation Hospital, Sequoia Capital Operations LLC, Fidelity Management Services Inc, and E Fund Management Co. Ltd
Key Investors in dMed Biopharmaceutical
Sequoia Capital Operations LLC
A premier global venture capital firm with an extensive track record of backing market-leading companies across technology and healthcare sectors, providing long-term strategic value to its portfolio.
Qiming Venture Capital
A prominent venture capital firm focused on innovative healthcare and technology companies, offering deep industry resources and strategic guidance to foster significant market growth.
Legend Capital
A long-standing private equity fund manager specializing in growth-stage enterprises with a strong focus on innovation and operational excellence within the Chinese market and beyond.
What's next for dMed Biopharmaceutical?
Looking ahead, the strategic deployment of $100M is expected to catalyze dMed Biopharmaceutical's expansion into new therapeutic areas and advanced clinical trial technologies. As the firm moves deeper into its enterprise-level lifecycle stage, the focus will likely shift toward optimizing its global network and integrating digital health solutions to further reduce trial timelines. By maintaining its commitment to high-quality data and patient-centric research, the company is poised to strengthen its role as an indispensable partner in the global biopharma ecosystem, potentially setting the stage for further market consolidation or long-term strategic partnerships.
See full dMed Biopharmaceutical company page
